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Abstract
Background: Mucolipidosis types II and III (ML II/III) are autosomal recessive disorders caused by a deficiency in the
lysosomal enzyme N-acetylglucosamine-1-phosphotransferase. We investigated the molecular genetic characteristics
of the GNPTAB gene, which codes for the alpha/beta subunits of a phosphotransferase, in Korean ML II/III patients.
We included prenatal tests and evaluated the spectrum of mutations in East Asian populations with ML II/III
through a literature review.
Methods: Seven patients from six families were enrolled in the study including two prenatal tests using chorionic
villi samples. A diagnosis of ML II/III was made based on clinical findings and increases in serum lysosomal enzyme
levels. PCR and direct sequencing were performed to identify GNPTAB mutations.
Results: We found 14 mutant alleles including seven known mutations of c.2189delT (p.Leu730fs*7), c.1090C > T
(p.Arg364*), c.2681G > A (p.Trp894*), c.3565C > T (p.Arg1189*), c.310C > T (p.Gln104*), c.1071G > A (p.Trp357*) and
c.2574_2575delGA (p.Asn859Glnfs*2). Four were novel variants of unknown significance: c.992A > G (p.Tyr331Cys),
c.2666 T > A (p.Leu889*), c.637-6 T > G (p.Thr213Phefs*11), and c.471_472delTT (p.Tyr158Serfs*8). Family studies
revealed the probands to be compound heterozygotes. The fetuses carried the same GNPTAB mutations as the
mucolipidosis II/III probands in the prenatal diagnosis.
Conclusions: We identified GNPTAB mutations in all patients with ML II/III, but did not identify a hot spot in
Korean patients. We successfully performed prenatal diagnosis using molecular investigation.
Keywords: GNPTAB, Lysosomal storage disease, Mucolipidosis, Prenatal diagnosis
Background
Mucolipidosis type II/III (ML II/III) is an autosomal
recessive inborn error resulted from the accumulation
of lysosomal substrates. This rare metabolic disorder is
caused by a deficiency of UDP-GlcNAc-1-phospho-
transferase, an enzyme responsible for the synthesis of
mannose-6-phosphate (M6P), a recognition marker in
the cis part of the Golgi apparatus [1, 2]. The loss of
M6P recognition results in impaired trafficking of lyso-
somal hydrolases and eventual lysosomal dysfunction.
ML was initially described in 1967 as a disease similar
to mucopolysaccharidosis (MPS) that presented with
different features such as low urinary acid mucopoly-
saccharides and abundant inclusions in fibroblasts [3].
For this reason, ML II wasoriginally called Inclusion Cell
or I-Cell disease. ML II is characterized by coarse facial
features, short stature, hyperplastic gums, organomegaly,
and retarded psychomotor development [4]. ML III,
originallyknown as pseudo-Hurler polydystrophy, was
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described Hurler-like disorder without mucopolysac-
chariduia [5]. ML III is a milder disorder with attenuated
characteristics and survival to adult life. It is allelic to
ML II and has a closely related pathogenesis. GlcNAc-
1-phosphotransferase is absent in MLII and lacking in
ML III. Intermediate forms of ML II and III have been
previously described [6]. GlcNAc-1-phosphotransferase
is composed of alpha, beta, and gamma subunits, and
ML II/III is caused by mutations in GNPTAB, which
encodes for the alpha and beta subunits of the phos-
photransferase [7].
The diagnosis of ML II/III is based on clinical, radio-
logical, biochemical, and molecular findings. Of these, a
mutation study of GNPTAB is important in terms of
confirmation of disease and prediction of prognosis. In
addition, a molecular analysis of GNPTAB is essential
for prenatal diagnosis of ML II/III [8]. In the present
study, we investigated GNPTAB mutations in five pa-
tients with ML II/III and successfully performed prenatal
testing in two pregnant women. In addition, genotypes
in Korean patients with ML II/III and the GNPTAB
mutation spectrum in East Asian populations with ML
II/III were studied through a literature review.
Methods
Patients
Seven individuals from six families were enrolled in the
study, including two obtained via prenatal genetic testing
using chorionic villi samples (CVSs). Prenatal genetic
test was done in case 3 and 4 because they had affected
older siblings. In addition, familial studies in cases 3, 5, 6
and 7 were performed. The median age of probands at
diagnosis was three years (range, 0.5–7 years), and only
one patient was male. A diagnosis of ML II/III was
performed based on clinical symptoms and abnormal
findings of lysosomal enzyme levels in blood. The study
was approved by the Institutional Ethics Committee of
Samsung Medical Center (IRB #2015-11-120-001).
Enzyme assays
Lysosomal activity, including that of β-hexosaminidase,
β-glucosidase, α-N-acetylglucosaminidase, in the plasma
and leukocytes was measured using methylumbelliferyl
substrates in spectrofluorometry (Beckman Coulter DU-
650, Fullerton, CA) at wavelengths of 360 and 448 nm.
Arysulfatase A was measured using the substrate p-
nitrocatechol sulfate. Enzyme activities of Cases 5 and 6
were measured at an outside hospital.
PCR and sequencing
Genomic DNA was extracted from peripheral blood leu-
kocytes with the Wizard Genomic DNA Purification Kit
(Promega, Madison, WI, USA) according to the
manufacturer’s recommendations. All 21 exons along
with flanking regions of the GNPTAB gene were ampli-
fied using PCR with primers (Table 1) designed by the
authors (Model 9700: Applied Biosystems, Foster City,
CA, USA). For reverse transcription PCR (RT-PCR),
cDNA corresponding to exons 6–8 was amplified with
primers (forward: actaaggatgttgaagatgccc, reverse: tcctgc
ttagactggctgatg) by use of cDNA Synthesis Kit (Applied
Biosystems). The amplified products were sequenced
using the BigDye Terminator Cycle Sequencing Ready
Reaction Kit (Applied Biosystems) on an ABI Prism
3100 Genetic Analyzer (Applied Biosystems). Nucleotides
were numbered according to the corresponding GenBank
accession number of GNPTAB (NM_024312.4).
Novel missense variation mutations were analyzed for
mutational possibility using in silico analysis through
Polymorphism Phenotyping-2 (PolyPhen-2) [9] and
Sorting Intolerant from Tolerant (SIFT) [10]. The 1000
Genomes Project data [11], the Exome Aggregation
Consortium [12], and the NCBI database of Single
Nucleotide Polymorphisms (dbSNPs) were checked for
known sequence variants. Evolutionary conservation of
amino acid residues in various species was assessed
using the EVOLA website (http://www.h-invitational.jp/
evola_main/annotation.cgi?hit=HIT000331461).
Results
The common disease-related symptoms at diagnosis
were short stature, multiple joint contracture, coarse
face, and developmental delay. Patients with ML II
showed typical coarse face: flat face, shallow orbits, de-
pressed nasal bridge, prominent mouth, and gingival
hypertrophy. Patients with ML III showed mild coarse
face without gingival hypertrophy. Only Patient 7
showed hepatosplenomegaly. Patient 1, 2, 5, 6, and 7
showed mild thickness of heart valves. Patients with
ML II showed remarkably height less than −2.2 stand-
ard deviation score (SDS), and patients with ML III
showed relatively short stature (−2 ~ −0.5 SDS). Clinical
information and identified mutations are summarized
in Table 2.
The representative radiographs of ML II and III are
shown in Figs. 1 and 2, respectively. Radiographs of
patient 7 with ML II at the age of 21 months show
features reminiscent of “osteitis fibrosa cystica” in Fig. 1.
Erosive changes, especially in the hands and hips, are
seen (Fig. 1a, b). The proximal phalanges are broad and
under-modelled. The proximal metacarpals show a
mixture of features of osteodystrophy and dysostosis
multiplex, becoming eroded and narrowed to a point.
The carpal bones are osteopenic and hypoplastic. There
is also over-modelling of the long bones and bowing of
the proximal end of the femur leading to coxa valga or
a or s also over-modelling of the long bones and
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bowing of the proximal hypoplastic and resorbed
(Fig. 1b). In addition, there is osteopenia of the spine.
The spine shows thoracolumbar kyphosis, beaking of
the vertebrae (Fig. 1c), and the skull shows J-shaped
sella turcica (Fig. 1d), which are typical of lysosomal
storage disorders with skeletal involvement.
Radiographs of patient 6 with ML III at the age of
19 years are shown in Fig. 2. The characteristic radio-
logic findings of the hands are small and irregular
carpal bones and relatively wide proximal phalanges
(Fig. 2a). In the lumbar spine, irregular delineation of
the vertebral bodies is seen (Fig. 2b). In the pelvis, pro-
gressive hip dysplasia with a flattened acetabulum and
femoral head destruction are seen (Fig. 2c). The plasma
levels of lysosomal enzyme activities were measured,
excluding those in Cases 3 and 4, and are listed in
Table 3. The plasma activity of lysosomal hydrolases
tested showed a 5- to 25-fold increase in upper refer-
ence limit as follows: Arysulfatase A (x25), α-N-
acetylglucosaminidase (x5 ~ 26), and β-hexosaminidase
(x7 ~ 24). Otherwise, the activities of none of these en-
zymes were increased in leukocytes.
Fourteen mutant alleles including seven known
(c.2189delT (p.Leu730fs*7), c.1090C > T (p.Arg364*),
c.2681G > A (p.Trp894*), c.3565C > T (p.Arg1189*),
c.310C > T (p.Gln104*), c.1071G > A (p.Trp357*) and
c.2574_2575delGA (p.Asn859Glnfs*2)) and four novel
(missense, nonsense, frameshift, and splicing mutations)
mutations were detected. The four novel mutations were
c.992A > G (p.Tyr331Cys), c.2666 T > A (p.Leu889*),
c.637-6 T > G, and c.471_472delTT (p.Tyr158Serfs*8).
All were absent in the healthy controls of the 1000
Genomes Project and Exome Aggregation Consortium
data. Cases 5 and 6 are siblings; they are the second
and third of three children, where the eldest child has a
normal phenotype. The family study of Cases 5 and 6
revealed the mutation c.637-6 T > G in a father and the
eldest sister, and c.2574_2575delGA in a mother. In
order to determine a possible splicing aberration of
c.637-6 T > G, RT-PCR sequencing in case 6 was per-
formed. The result revealed that a new splice site was
observed which leads to an insertion of 5 nucleotides
and a premature stop codon (p.Thr213Phefs*11) (Fig. 3).
A family study of Case 3 and 7 was also performed,
Table 1 Sequences of Primers Used for PCR amplification and
Sequencing of GNPTAB
Exon Primers
1 F: ctatgcccctccgtcctc
R: gctcaggagttcgagaccag
2 F: ttgtccttttcaggaactgtagc
R: cacaggggccacactaatct
3 F: cccccagctacagtttgaa
R: acctccacctcccaaagttc
4 F: ggccaccttatattggagca
R: actctaaccctccccagtgc
5 F: tccatgagataaaagtcttcatttg
R: gcagctgttttgcttctcttt
6 F: tcccatgaagaattcccttt
R: gcatcacaacacaagcttcaa
7 F: gctgtttttctttgagaatcttttt
R: aaggagtgaggctcttctgg
8 F: ggaggttgaggtgagcagag
R: taccaaaccaatggcagtga
9 F: aatgctgtctctttgaattttgg
R: gagagctgtttgggtttggt
10 F: ccctttacccttctacctcca
R: tatgcttcccaagctggtct
11 F: tcaacgcagcaggatctaaa
R: actcctcccagctcagcttt
12 F: tgatccagcctcctctgc
R: cctcttcagtgatttatgttgttctc
13_1 F: cacaaggacgacatgcaaat
R: cgtaacccttctgggctgta
13_2 F: tgatccttctcccaaaccag
R: tgatctcagcaaggctgact
13_3 F: aggcggaaatcctttttgag
R: aatcagagatgggggctttt
13_4 F: gctccacaggaaaaacaggt
R: aaatgaaaccatgtaagaaaagca
14 F: tgacccgttaacatgtatttca
R: catttgcagagatggacttttt
15 F: tgctcgtgtttgagttgtttg
R: ggttggtctcgaactcctga
16 F: ttggcattgtctcattctgc
R: ttacgcatctatggggtgaa
17 F: ggtttggtttgtgaaaaatgc
R: ccgtagtggactcaacatcca
18 F: aatcacaaaggtctggcttttt
R: atgggggaccctatctcaac
19 F: tcattcccccagagaatcat
Table 1 Sequences of Primers Used for PCR amplification and
Sequencing of GNPTAB (Continued)
R: aggttgcagtgagctgaggt
20 F: cctctctcctgcctggataa
R: tgctgcctgaatattgtgaaa
21 F: ttttggaagaggaatgatgga
R: aggatgacaggtccatgagc
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which revealed the probands to be compound heterozy-
gous. No family members who participated in the
family study were affected individuals, and all had a
heterozygous mutant allele. Cases 3 and 4 were prenatal
tests with chorionic villi sampling in which the fetus
carried the same GNPTAB mutations as the ML II/III
probands.
All reported GNPTAB mutations in Korean patients
with ML II/III are listed in Table 4. A total of 14 muta-
tions have been reported in the Korean population, in-
cluding those from this study. The most common type
of mutation was a nonsense mutation (50%), followed
by frameshift (31%), splicing (13%), and missense (6%)
mutations. Frameshift mutation is the most common
mutation in Asian populations (52%). All mutations re-
ported in Asian populations are summarized in Table 5.
The c.3565C > T (p.Arg1189*) mutation was most fre-
quently observed in Korean and Japanese populations
(11.5 and 32.5%).
Discussion
In this study, five patients with ML II/III were confirmed
through molecular genetic testing, and two cases were
successfully screened using prenatal tests. A total of 14
mutant alleles were found in seven cases of ML II/III,
and four of them were novel. Among four novel
GNPTAB mutations, c.992A > G (p.Tyr331Cys) was the
first missense variation detected in a Korean patient with
ML II/III. There were no other missense variations in
Korean ML II/III patients. The novel c.992A >G variation
was considered to be a likely pathogenic variant because
the effect of the amino acid change of p.Tyr331Cys was
predicted to be “likely damaging” by PolyPhen-2 and “not
tolerated” by SIFT. In addition, p.Tyr331 is a highly con-
served region among several species (Fig. 4). Evolutionary
conservation of the amino acid residues for p.Tyr331
has been observed in various mammals and zebrafish
(Homo sapiens, Pan troglodytes, Pongo pygmaeus,
Macaca mulatta, Mus musculus, Rattus norvegicus,
Table 2 Clinical characteristics and GNPTAB mutations in seven patients with ML II/III
Case no. Phenotype Age at Dx.
(month)
Sex Symptoms at diagnosis Nucleotide change
Nucleotide change
Amino acid
change
1 III 3.10 M growth retardation, joint contracture, developmental delay c.992A > G
c.2189delT
p.Tyr331Cys
p.Leu730fs*7
2 II 0.5 F developmental delay, synostosis, puffy face c.1090C > T
c.2666 T > A
p.Arg364*
p.Leu889*
3a NA NA F normal, prior affected sibling c.2681G > A
c.3565C > T
p.Trp894*
p.Arg1189*
4a NA NA F normal, prior affected sibling c.310C > T
c.3565C > T
p.Gln104*
p.Arg1189*
5 III 7.3 F mental retardation, asymmetric chest, joint contracture, c.637-6 T > G
c.2574_2575delGA
p.Thr213Phefs*11
p.Asn859Glnfs*2
6 III 6.3 F joint contracture c.637-6 T > G
c.2574_2575delGA
p.Thr213Phefs*11
p.Asn859Glnfs*2
7 II 1.8 F growth retardation, joint contracture, puffy face, hepatosplenomegaly c.471_472delTT
c.1071G > A
p.Tyr158Serfs*8
p.Trp357*
aPrenatal test, Dx diagnosis, NA not applicable
Fig. 1 Radiographs of 21-month-old Korean girl with ML II. a Radiograph of hands and wrists showing broad and under-modelled proximal
phalanges (bullet-shaped) and proximal pointing of metacarpals. b Radiograph of pelvis and proximal femurs showing dysplasia/resorption
of the lower third of the ilia femoral heads and femoral necks and e. Clierd’s crook deformity.” c Radiograph of spine showing thoracolumbar
kyphosis and beaking of the vertebrae. d Radiograph of skull showing J-shaped sella turcica
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Canis lupusfamiliaris, Equus caballus, Bos Taurus,
Monodelphis domestica, and Danio rerio).
Another novel splicing mutation (c.637-6 T > G) was
observed in two sisters (Cases 5 and 6). Their father and
eldest sister were heterozygous carriers of the c.637-
6 T > G mutation. RT-PCR sequencing revealed that this
mutation created a new cryptic 3′ splice site resulting
in truncated proteins. Although there have been some
reports describing molecular genetic analyses of MLs,
there were a few reports in the Korean population. No
homozygotes were observed in the present study or in
other studies on the Korean population [13, 14], while
homozygotes have been detected in the Chinese and
Japanese populations [15, 16].
To date, three cases in the Korean population have
been identified to be compound heterozygotes for two
nonsense mutations; both were patients with ML II. The
affected children of the prenatal diagnosis cases (Cases 3
and 4), the probands reported by Paik et al. [13], had
cardiac anomalies of coronary artery atresia or mitral
valve prolapse and expired at 13 years and 3 years of
age, respectively. In addition, compound heterozygotes
for a nonsense and frameshift mutation also exhibited
the ML II phenotype. On the other hand, patients that
were heterozygous for at least one allele with a missense
or splicing mutation demonstrated an attenuated pheno-
type. This genotype-phenotype correlation in ML II/III
is compatible with the results described in previous re-
ports [13, 17–19]. Genotypes with compound heterozy-
gotes consisting of nonsense and frameshift mutations
are expected to produce no RNA product, and they are
associated with a more severe phenotype (ML II). Thus,
phenotype seems to be well correlated with genotype in
13 Korean patients.
Fig. 2 Radiographs of 19-year-old Korean female with ML III. a Radiograph of hands and wrists showing claw hands: impossible flexion and
maximum extension without objective skin thickening or joint involvement. Small and irregular carpal bones and wide proximal phalanges
are noted. b Radiograph of spine showing irregularity of the vertebral end plates. c Radiograph of pelvis showing flattened acetabulum and
femoral head deformity
Table 3 Lysosomal enzyme activities in patients with ML II/III
Case no. Reference range Reference range a
1 2 5a 6a 7 (nmol/hr/mg) (nmol/min/mL)
Arylsulfatase A
Plasma 847 312 42 43 2228 NA 0.1–1.6
Leukocyte 66 26 NA NA 38 25–80 NA
α-N-Acetylglucosaminidase
Plasma 234 NA 9 NA NA 22.3–60.9 0.1–0.6
Leukocyte 0.93 NA NA NA NA 0.90–1.51 NA
β-Hexosaminidase
Plasma 4520 12247 14 13 8196 374–666 0.5–3.1
Leukocyte 728 482 NA NA 358 611–991 NA
β-Glucosidase
Plasma 0.7 0.4 NA NA 0.86 NA NA
Leukocyte 7.0 9.2 NA NA 8.3 5.1–11.32 NA
β-Glucuronidase
Plasma NA NA 18 19 NA NA 0.1–2.0
Leukocyte NA NA NA NA NA NA NA
NA not available; aperformed at outside hospital
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According to the Human Gene Mutation Database,
more than 130 GNPTAB mutations have been reported in
patients with ML II/III [20]. Figure 5 shows the GNPTAB
mutation spectrum according to ethnic population with
ML II/III. A missense mutation is the most abundant type
of mutation (27%), and a small deletion is the next most
common (25%). In the Korean population, however, only
one missense mutation (6%) has been observed to date,
while nonsense mutations make up 50% of mutations
[13, 14]. In a Japanese population, frameshifts were the
most common mutation type (61%), and missense mu-
tations were relatively common (22%); the frequently
observed mutation c.3565C > T (p.Arg1189*) had an al-
lele frequency of 32.5% [15]. In a Korean population,
the most frequently observed mutation was c.3565C > T
(p.Arg1189*) (11.5%, 5/26 alleles), excluding the over-
lapping case of siblings, but the difference in frequency
compared to the second most common mutation
(c.2574_2575delGA, 7.7%) was not large. The c.3503delTC
mutation, known as a single causal mutation in a French-
Fig. 3 Molecular effects of the c.637-6 T > G mutation. a A schematic representation and cDNA sequence from case 6. b The predicted amino
acid sequence (inserted nucleotides are shaded)
Table 4 GNPTAB mutations in 13 Korean patients with ML II/III
Mutation type Exon no. Nucleotide change Amino acid change No. of alleles Reference
Missense 9 c.992A > G p.Tyr331Cys 1 This study
Nonsense 3 c.310C > T p.Gln104* 2 [13], This study
Nonsense 9 c.1071G > A p.Trp357* 1 This study
Nonsense 9 c.1090C > T p.Arg364* 1 This study
Nonsense 13 c.2666 T > A p.Leu889* 1 This study
Nonsense 13 c.2681G > A p.Trp894* 2 [13], This study
Nonsense 15 c.3091C > T p.Arg1031* 1 [14]
Nonsense 16 c.3173C > G p.Ser1058* 1 [13]
Nonsense 19 c.3565C > T p.Arg1189* 5 [13], This study
Frameshift 5 C.471_472delTT p.Tyr158Serfs*8 1 This study
Frameshift 13 c.2189delT p.Leu730fs*7 1 This study
Frameshift 13 c.2574_2575delGA p.Asn859Glnfs*2 3 [13], This study
Frameshift 19 c.3456_3459dupCAAC p.Ile1154Glnfs*3 1 [14]
Frameshift 19 c.3474_3475delTA p.His1158fs*15 1 [13]
Splicing IVS6 c.637-6 T > G p.Thr213Phefs*11 2 This study
Splicing IVS13 c.2715 + 1G > A - 2 [13]
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Table 5 Summary of all reported GNPTAB mutations in East Asian patients with ML II/III
Mutation type Nucleotide change Amino acid change Exon no. Reference Allele frequency Ethnicity
Missense c.992A > G p.Tyr331Cys 9 This study 0.9% (1/120) KOR
Missense c.1001G > T p.Arg334Leu 9 [15] 0.9% (1/120) JPN
Missense c.1120 T > C p.Phe374Leu 10 [15] 6.7% (8/120) JPN
Missense c.2866C > T p.His956Tyr 14 [15] 1.8% (2/120) JPN
Missense c.3458A > G p.Asn1153Ser 19 [15] 0.9% (1/120) JPN
Nonsense c.310C > T p.Gln104* 3 [13, 15], This study 5.3% (6/120) KOR, JPN
Nonsense c.1071G > A p.Trp357* 9 [16], This study 2.7% (3/120) KOR, CHN
Nonsense c.1090C > T p.Arg364* 9 [16, 23], This study 5.9% (7/120) KOR, CHN
Nonsense c.2666 T > A p.Leu889* 13 This study 0.9% (1/120) KOR
Nonsense c.2681G > A p.Trp894* 13 [13, 15], This study 3.4% (4/120) KOR, JPN
Nonsense c.3091C > T p.Arg1031* 15 [14] 0.9% (1/120) KOR
Nonsense c.3173C > G p.Ser1058* 16 [13] 0.9% (1/120) KOR
Nonsense c.3565C > T p.Arg1189* 19 [13, 15, 24], This study 32.5% (39/120) KOR, JPN, CHN
Frameshift c.471_472delTT p.Tyr158Serfs*8 5 This study 0.9% (1/120) KOR
Frameshift c.914_915insA p.Asp305fs 8 [15] 0.9% (1/120) JPN
Frameshift c.2089_2090insC p.Leu697fs 13 [15] 1.8% (2/120) JPN
Frameshift c.2189delT p.Leu730fs*7 13 This study 0.9% (1/120) KOR
Frameshift c.2422delC p.Leu808fs*19 13 [24] 0.9% (1/120) CHN
Frameshift c.2427delC p.Leu810fs 13 [15] 0.9% (1/120) JPN
Frameshift c.2544delA p.Lys848fs 13 [15] 1.8% (4/120) JPN
Frameshift c.2574_2575delGA p.Asn859Glnfs*2 13 [13], This study 2.5% (3/120) KOR
Frameshift c.2693delA p.Lys898fs 13 [15] 0.9% (1/120) JPN
Frameshift c.3310delG p.Ala1104fs 17 [15] 0.9% (1/120) JPN
Frameshift c.3388_3389insC + c.3390C > T p.Val1130fs 18 [15] 0.9% (1/120) JPN
Frameshift c.3428_3429insA p.Asn1143fs 18 [15] 0.9% (1/120) JPN
Frameshift c.3456_3459dupCAAC p.Ile1154Glnfs*3 19 [14] 0.9% (1/120) KOR
Frameshift c.3474_3475delTA p.His1158fs*15 19 [13] 0.9% (1/120) KOR
Frameshift c.3741_3744delAGAA p.Glu1248fs 21 [15] 0.9% (1/120) JPN
Frameshift duplication exon2 Frameshift 2 [15] 5.0% (6/120) JPN
Splicing c.637-6 T > G p.Thr213Phefs*11 IVS6 This study 1.8% (2/120) KOR
Splicing c.2715 + 1G > A - IVS13 [13, 15, 23] 7.5% (9/120) KOR, JPN, CHN
CHN Chinese, JPN Japanese, KOR Korean
Fig. 4 Evolutionary conservation of the amino acid residues of a novel missense, likely pathogenic variant. The affected residue, Tyr331, is strictly
conserved in various mammals and zebrafish
Yang et al. Orphanet Journal of Rare Diseases  (2017) 12:11 Page 7 of 9
Canadian founder population [21], was the most fre-
quently encountered mutation in the largest study in a
Western population [19]. Considering that c.3503delTC
has not been observed in Asian populations, the spectrum
of mutation type seems to exhibit ethnic differences.
In this study, two prenatal tests with CVS were success-
fully performed, revealing the same mutations as those
present in the probands. To the best of our knowledge,
only one case has been published on the prenatal diagno-
sis of ML II/III by means of molecular study [8]. In Korea,
a prenatal test of ML II/III is legal, and this is the first case
of prenatal investigation of ML II/III. As there are cur-
rently no effective therapies such as hematopoietic stem
cell transplantation [22], a prenatal test for this mutation
is expected to simply provide information to the parents
of probands with ML II/III.
Conclusions
The direct measurement of UDP-GlcNAc-1-phospho-
transferase is complicated and not available in many
countries. In addition, enzyme assays might have some
limitations in terms of interpretation. Thus, molecular
genetic investigation is clinically very useful in the diagno-
sis of ML II/III patients. In this respect, GNPTAB genotyp-
ing is essential to confirm the diagnosis of ML II/III and is
helpful for distinguishing carriers via prenatal diagnosis.
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